A furan carboxylic acid compound from purslane and its extraction and separation method and use

Abstract

The present invention belongs to the technical field of extraction and separation of traditional Chinese medicines, and relates to a furan carboxylic acid compound in Portulaca oleracea, and its extraction and separation method and use. The new compound has a molecular formula of C6H6O5 and a chemical name of 2-hydroxy-5-methoxyfuran-3-carboxylic acid. A method for extracting and separating the new compound is also provided, which sequentially uses water decoction extraction, macroporous resin column chromatography, ODS column chromatography, dextran gel column (Sephadex LH-20) chromatography and high performance liquid chromatography for separation, purification and preparation. Its structure is determined to be a new compound using mass spectrometry, hydrogen spectrum, carbon spectrum and two-dimensional nuclear magnetic spectrum analysis methods. The new compound has anti-inflammatory activity, anticholinesterase activity and antioxidant activity. The new compound of the present invention and its salt or derivative can be used as raw materials for drug development and pharmacological activity research.

Description

Technical Field

[0001] The present invention belongs to the technical field of extraction and separation of traditional Chinese medicines, and relates to a furan carboxylic acid compound in purslane, an extraction and separation method and use thereof, and in particular to a new compound 2-hydroxy-5-methoxyfuran-3-carboxylic acid extracted, separated and identified from purslane, and an extraction and separation method thereof. Background Art

[0002] Purslane, derived from the dried aerial parts of Portulaca oleracea L., is a wild plant designated by my country's National Health Commission as both a medicine and a food. Also known as longevity vegetable and five-element grass, purslane has been used as a traditional Chinese medicine for thousands of years. Widely distributed and abundant in resources, it possesses exceptional adaptability and tenacious vitality. The 2020 edition of the Pharmacopoeia of the People's Republic of China lists the dried aerial parts of purslane as a medicinal herb. It has a sour and cold flavor and enters the liver and large intestine meridians. It has the effects of clearing heat and detoxifying, cooling blood and stopping bleeding, and stopping dysentery. It is used for heat-toxic bloody dysentery, carbuncles, furuncles, eczema, erysipelas, snake and insect bites, blood in stool, hemorrhoids, and metrorrhagia.

[0003] Modern research indicates that Portulaca oleracea possesses anti-inflammatory, antioxidant, anticholinesterase, antitumor, lipid-lowering, and antimicrobial effects, primarily attributable to its bioactive components, such as alkaloids, flavonoids, lignans, organic acids, terpenes, furans, polysaccharides, and phenolic acids. Alkaloids, in particular, have been shown to exhibit significant anti-inflammatory effects. Portulaca oleracea contains a wide variety of chemical components with diverse pharmacological activities. The discovery and isolation of compounds from Portulaca oleracea provides a foundation for in-depth research on the plant. Summary of the Invention

[0004] To address the above problems, the present invention provides a furan carboxylic acid compound extracted from Portulaca oleracea. Studies have found that the furan carboxylic acid compound of the present invention has anti-inflammatory activity, anticholinesterase activity and antioxidant activity; at the same time, a simple, rapid, environmentally friendly and high-purity extraction and separation method for the compound of the present invention is provided.

[0005] To achieve the above-mentioned purpose of the present invention, the present invention provides a new furan carboxylic acid compound, the molecular formula of which is C6H6O5, named 2-hydroxy-5-methoxyfuran-3-carboxylic acid according to the structure, and the chemical structure is:

[0006]

[0007] 2-hydroxy-5-methoxyfuran-3-carboxylic acid

[0008] The present invention also provides a method for extracting and separating a furan carboxylic acid compound (2-hydroxy-5-methoxyfuran-3-carboxylic acid), which specifically comprises the following steps:

[0009] Step 1: Take dried purslane, decoct in water and extract, concentrate the extract, cool to room temperature, and set aside the medicinal solution.

[0010] Step 2: The concentrated solution in step 1 is subjected to macroporous resin, and eluted with water and ethanol of different concentrations, and the 50% ethanol portion is recovered under reduced pressure to obtain an extract to obtain a concentrate for use.

[0011] Step 3: Separate the concentrate in step 2 through an ODS column (Octadecylsilyl, octadecylsilane bonded silica gel filler) using a methanol-water gradient elution, detect by thin layer chromatography, develop color, combine the 5% methanol elution fractions, and evaporate to dryness to obtain a concentrate for use.

[0012] Step 4: The concentrate obtained in step 3 is further separated by ODS column chromatography, using a methanol-water gradient elution, detected by thin layer chromatography, and color developed. The 20% methanol elution portion is combined and evaporated to dryness to obtain a concentrate for use.

[0013] Step 5: The product obtained in step 4 is further chromatographed on a pretreated Sephadex LH-20 column and isocratically eluted with 30% methanol to obtain several elution fractions, which are detected by thin layer chromatography, developed, and combined. The combined elution fractions are concentrated to dryness under reduced pressure and set aside;

[0014] Step 6: The concentrate obtained in step 5 is separated and prepared by HPLC (high performance liquid chromatography), and isocratic elution is performed using methanol-0.1% formic acid (volume percentage) as the mobile phase to finally obtain the new furan carboxylic acid compound of the present invention.

[0015] Furthermore, in step 1, the extraction is performed twice with water decoction, each time for 2 hours, and the amount of water used is 8 to 16 times the amount of the medicinal material.

[0016] Furthermore, in step 2, the macroporous resin used is AB-8 macroporous resin, and the volume ratios of ethanol and water used are 30:70, 50:50, 70:30 and 100:0.

[0017] Furthermore, in step 3, the volume ratio of methanol to water is 5:95, 20:80, 40:60, 80:20 and 100:0; and the particle size of ODS is 40-70 μm.

[0018] Furthermore, in step 4, the volume ratio of methanol to water is 5:95, 20:80, 40:60, 80:20 and 100:0; and the particle size of ODS is 40-70 μm.

[0019] Furthermore, in step 5, the methanol elution procedure is 30% methanol isocratic elution.

[0020] Furthermore, the pretreatment process of the ODS and dextran gel is to soak them in methanol for 24 hours; load them onto the column, wash them with methanol until there is no turbidity when dripping into water, and then balance them with the initial mobile phase.

[0021] Furthermore, in step 6, the volume ratio of methanol to 0.1% formic acid is 20:80, and the retention time of the compound is 13.710 min.

[0022] The pretreatment process of the ODS and dextran gel is as follows: soaking in methanol for 24 hours, loading onto the column, washing with methanol until no turbidity is observed when dripped into water, and then balancing with the initial mobile phase.

[0023] The present invention also provides a use of the 2-hydroxy-5-methoxyfuran-3-carboxylic acid isolated from the purslane medicinal material in the preparation of anti-inflammatory drugs, anticholinesterase drugs and antioxidant drugs.

[0024] Compared with the prior art, the present invention has the following beneficial effects.

[0025] The isolation and pharmacological activity research of 2-hydroxy-5-methoxyfuran-3-carboxylic acid from purslane described in the present invention have not been reported in plants. The present invention provides a new furancarboxylic acid compound derived from purslane and a method for extracting and isolating the compound of the present invention. The method sequentially employs water decoction extraction, macroporous resin column chromatography, ODS column chromatography, Sephadex LH-20 column chromatography, and high-performance liquid chromatography for separation, purification, and preparation to successfully extract and isolate a new furancarboxylic acid compound. The method has only six steps and is simple and rapid. The extraction is performed using water, making the process environmentally friendly. The compound isolated by the method has a high purity of greater than 90%. In addition, studies have shown that the above compound has anti-inflammatory, anticholinesterase, and antioxidant activities. Therefore, the new compound 2-hydroxy-5-methoxyfuran-3-carboxylic acid and its salts and derivatives can be used as raw materials for drug development and pharmacological activity research. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1The novel compound 2-hydroxy-5-methoxyfuran-3-carboxylic acid of the present invention 1 H-NMR spectrum.

[0027] Figure 2 The novel compound 2-hydroxy-5-methoxyfuran-3-carboxylic acid of the present invention 13 C-NMR spectrum.

[0028] Figure 3 The DEPT spectrum of the new compound 2-hydroxy-5-methoxyfuran-3-carboxylic acid of the present invention is shown in FIG.

[0029] Figure 4 This is the HSQC spectrum of the new compound 2-hydroxy-5-methoxyfuran-3-carboxylic acid of the present invention.

[0030] Figure 5 This is the HMBC spectrum of the new compound 2-hydroxy-5-methoxyfuran-3-carboxylic acid of the present invention.

[0031] Figure 6 The COESY spectrum of the new compound 2-hydroxy-5-methoxyfuran-3-carboxylic acid of the present invention is shown in FIG.

[0032] Figure 7 The figure is the ROESY spectrum of the new compound 2-hydroxy-5-methoxyfuran-3-carboxylic acid of the present invention.

[0033] Figure 8 This is a high-resolution mass spectrum of the new compound 2-hydroxy-5-methoxyfuran-3-carboxylic acid of the present invention. DETAILED DESCRIPTION

[0034] The following examples will help to understand the present invention, but these examples are only for illustration of the present invention and the present invention is not limited to these contents. The operating methods in the examples are all conventional operating methods in the art.

[0035] Example 1.

[0036] 2-hydroxy-5-methoxyfuran-3-carboxylic acid

[0037] The present invention provides a furan carboxylic acid compound with a molecular formula of C6H6O5, named 2-hydroxy-5-methoxyfuran-3-carboxylic acid according to the structural formula, and the chemical structural formula is:

[0038]

[0039] 2-hydroxy-5-methoxyfuran-3-carboxylic acid

[0040] Table 1 shows the NMR data of 2-hydroxy-5-methoxyfuran-3-carboxylic acid. The solvent used for NMR was CD3OD-d4.

[0041] Table 1: NMR data of 2-hydroxy-5-methoxyfuran-3-carboxylic acid of the present invention.

[0042]

[0043] 2-hydroxy-5-methoxyfuran-3-carboxylic acid: yellow oil, easily soluble in methanol. 1 H-NMR, 13 C-NMR and HR-ESI-TOF-MS signals indicate that the possible molecular formula of the compound is C6H6O5 with an unsaturation of 8. HR-ESI-TOF-MS gives m / z [M-OH] - The quasi-molecular ion peak is 141.0184, calculated value (C6H5O4 - =141.0188). 13 C-NMR and DEPT spectra show that there are 6 carbon resonance peaks in the compound, including 1 methoxy group (δ C 56.70), 1 methine (δ C 108.19), three quaternary carbon resonance peaks (δ C 148.82, 141.65, 122.02), 1 carbonyl group (δ C 169.93). The NMR data of the compound are listed in Table 1. 1 The H-NMR spectrum and HMBC spectrum showed that H-4 (δ H 7.33) and C-3(δ C 122.02), C-2(δ C 141.65), C-5(δ C 148.82) and C-7 (δC 169.93) and the chemical shifts of C-2 and C-5 are in the downfield, which proves that they are connected to O atoms respectively. It is speculated that there is a furan ring and that -COOH is connected to C-3. Due to the C-2 (δ C The chemical shift of 141.65) is in the downfield. In addition to being adjacent to the O atom in the furan ring, it is speculated that it is connected to -OH. Combined with the HR-ESI-TOF-MS mass spectrum, it is reasonable to infer that the compound contains hydroxyl groups, and the new compound can be confirmed to have the above structure.

[0044] The present invention also provides a method for extracting and separating 2-hydroxy-5-methoxyfuran-3-carboxylic acid, which comprises the following specific steps:

[0045] Step 1: Weigh 250 kg of dried purslane medicinal materials, use water decoction to extract, the amount of which is 10 times that of the medicinal materials, extract twice, each time for 2 hours, combine the extracts, heat and concentrate, cool to room temperature, and obtain the medicinal solution for use.

[0046] Step 2: The medicinal solution obtained in step 1 is evaporated to dryness and separated by chromatography on an AB-8 macroporous resin column using an ethanol-water (30:70, 50:50, 70:30 and 100:0, v:v) gradient elution. The 50% ethanol portion is collected and recovered under reduced pressure to obtain an extract to obtain a concentrate for later use.

[0047] Step 3: The concentrate in step 2 was separated by a pretreated ODS column with a filler particle size of 40 to 70 μm, and gradient elution was performed using methanol-water (5:95, 20:80, 40:60, 80:20 and 100:0, v / v). The mixture was detected by thin layer chromatography and color was developed. The 5% methanol elution fractions were combined, concentrated to dryness under reduced pressure, and set aside.

[0048] Step 4: The product obtained in step 3 is further separated by pre-treated ODS column chromatography using a filler with a particle size of 40-70 μm. The product is eluted with a gradient of methanol-water (5:95, 20:80, 40:60, 80:20, and 100:0, v / v). Thin layer chromatography is performed for detection and color development. The 20% methanol elution fractions are combined and concentrated to dryness under reduced pressure for later use. The ODS pre-treatment process is as follows: soaking in methanol for 24 hours. After loading the column, the column is washed with methanol until there is no turbidity when dripped into water, and then equilibrated with the initial mobile phase.

[0049] Step 5: The product obtained in Step 4 is further chromatographed on a pretreated Sephadex LH-20 column and isocratically eluted with 30% methanol to obtain several elution fractions. These fractions are then analyzed by thin-layer chromatography, combined, and concentrated to dryness under reduced pressure for later use. The pretreatment process for the Sephadex gel comprises soaking the column in methanol for 24 hours, loading the column, eluting with methanol until the column is free of turbidity when dropped into water, and then equilibrating with the initial mobile phase.

[0050] Step 6: The fraction obtained in step 5 was separated and prepared by HPLC using methanol and 0.1% formic acid in a volume ratio of 20:80 as the mobile phase and detection wavelengths of 210 and 254 nm to obtain the new compound of the present invention. The purity was determined to be 98% by normalization method.

[0051] Example 2.

[0052] The anti-inflammatory effect of the 2-hydroxy-5-methoxyfuran-3-carboxylic acid of the present invention.

[0053] 1 Main Materials

[0054] 1.1 Drugs and Reagents: The new compound used in this experiment was prepared by the above-mentioned method with a purity of 98%. DMEM high-glucose medium and fetal bovine serum were obtained from Hyclone (USA); penicillin and streptomycin were obtained from Hangzhou Sijiqing Company; LPS was obtained from Sigma (USA); ELISA kits for IL-1β and TNF-α were obtained from Cayman (USA); and cell lysate was used.

[0055] 1.2 Cell line: RAW264.7 macrophages (ATCC cell bank, USA)

[0056] 1.3 Grouping: Divided into control group, LPS group and experimental group.

[0057] 2 Experimental methods

[0058] 2.1 Cell culture: Add 10% fetal bovine serum and 1% antibiotics (100 U / mL penicillin and 100 μg / mL streptomycin) to DMEM high-glucose medium and store at 4°C.

[0059] 2.2 CCK-8 assay for cell viability: The three groups of RAW264.7 macrophages in logarithmic growth phase were inoculated into 96-well culture plates at a cell density of 1×10 4 / mL, 100μL per well, 37℃, 5% CO2, after overnight incubation, the experimental group was added with different concentrations of the compound of the present invention 2-hydroxy-5-methoxyfuran-3-carboxylic acid (5μM~50μM), incubated for 1h, and LPS at a concentration of 1μg / mL was added to the LPS group and experimental group respectively. A zero adjustment group (culture medium containing DMSO solvent) was also set up. Each group had 3 replicates to investigate the effect of drug addition on the cells. After 24h of incubation of the above-mentioned groups of cells, 10μL of CCK-8 was added to each well of cells, and incubated for another 4h at 37℃, 5% CO2. The absorbance of each well was measured at a wavelength of 450nm using a microplate reader.

[0060] 2.3 ELISA assay for inflammatory cytokines IL-1β and TNF-α: RAW264.7 macrophages in the logarithmic growth phase were seeded in 24-well culture plates at a cell density of 1×10 5 Cells were incubated overnight at 37°C in 5% CO2 with 1 mL per well. The experimental group was treated with the compound of this invention, 2-hydroxy-5-methoxyfuran-3-carboxylic acid (1 μM to 20 μM). After incubation for 1 hour, LPS (final concentration 1 μg / mL) was added to each well and incubated for 24 hours. Each treatment was repeated in triplicate. IL-1β and TNF-α levels were measured by ELISA.

[0061] 3 Experimental results

[0062] The experimental results show that the compound of the present invention has no effect on the proliferation of LPS-induced macrophages RAW264.7; it can effectively inhibit the secretion of excessive inflammatory cytokines IL-1β and TNF-α produced by LPS-induced macrophages RAW264.7 in a concentration-dependent manner.

[0063] The results of the relative cell survival rate experiment are shown in Table 2.

[0064] Table 2: Effects of the compounds of the present invention on the relative survival rate of RAW264.7 macrophages.

[0065]

[0066] The results of ELISA determination of inflammatory factors IL-1β and TNF-α are shown in Table 3.

[0067] Table 3: Effects of the compounds of the present invention on the levels of IL-1β and TNF-α secreted by RAW264.7 cells induced by LPS (mean ± standard deviation, n=3).

[0068]

[0069]

[0070] Note: * P<0.05 compared with the control group, # P<0.05 compared with the LPS group.

[0071] Example 3 Anticholinesterase effect of 2-hydroxy-5-methoxyfuran-3-carboxylic acid of the present invention.

[0072] 1 Main Materials

[0073] 1.1 Drugs and Reagents: The new compound used in the experiment was prepared by the above method with a purity of 96%. Physostigmine was obtained from Shanghai Hanxiang Biotechnology Co., Ltd., acetylcholine iodide (ATCI) and acetylcholinesterase (AChE) were obtained from Dalian Meilun Biotechnology Co., Ltd., dithiodinitroformic acid (DTNB) was obtained from Shanghai Jinshui Biotechnology Co., Ltd., and sodium dihydrogen phosphate and sodium dihydrogen phosphate were obtained from Shanghai Sinopharm Reagent Co., Ltd.

[0074] 1.2 Experimental instruments and equipment: HBS-1096A 96-well microplate reader (Nanjing Detie Experimental Equipment Co., Ltd.), 1 / 100,000 balance (METTLER, Switzerland), HH-4 digital display constant temperature water bath (Jiangsu Jintan Ronghua Instrument Manufacturing Co., Ltd.).

[0075] 2 Experimental methods

[0076] The anticholinesterase activity of each compound was determined using a modified Ellman method. 2-hydroxy-5-methoxyfuran-3-carboxylic acid and physostigmine were accurately weighed and prepared in methanol to prepare five concentration series of 31.25 μM, 62.5 μM, 125 μM, 250 μM, and 500 μM sample solutions. The specific operation is as follows: 140 μL of phosphate buffered saline (0.1 M, pH = 8.0, containing 0.1 mol / L sodium dihydrogen phosphate and sodium dihydrogen phosphate) was added to a 96-well microplate, 20 μL of sample solution, 15 μL of AChE (0.2 U / mL), and incubated at 37 ° C for 10 minutes. Then, 10 μL of ATCI (4 mmol / L) and 10 μL of DTNB (15 mmol / L) were added. After incubation at 37 ° C for 20 minutes, the 96-well plate was placed in a microplate reader and the absorbance of each group of samples was measured at a wavelength of 405 nm. Among them, methanol was used instead of the sample solution as the blank group, and physostigmine was used instead of the sample solution as the positive control group. The cholinesterase inhibition rate of each compound was calculated according to the following formula (A represents absorbance):

[0077] Inhibition rate (%) = (A 空白 -A样品 ) / A 空白 ×100%

[0078] 3 Experimental results

[0079] The experimental results show that the new compound of the present invention exhibits certain anticholinesterase activity, and the inhibitory effect on cholinesterase increases with the increase of the compound concentration, showing a dose-dependent trend.

[0080] The anticholinesterase activities of the novel compounds of the present invention are shown in Table 4.

[0081] Table 4: Anticholinesterase activity of the compounds of the present invention.

[0082]

[0083] Example 4 Antioxidant effect of 2-hydroxy-5-methoxyfuran-3-carboxylic acid of the present invention.

[0084] 1 Main Materials

[0085] 1.1 Drugs and Reagents: The new compound used in the experiment was prepared by the above method with a purity of 96%. 1,1-Diphenyl-2-picrylhydrazyl free radical (DPPH) was obtained from Sigma-Aldrich, USA; butylated hydroxyanisole (BHA) was obtained from Shanghai Xiangrui Biological Co., Ltd.; and methanol (chromatographically pure, Tianjin Kaixin Chemical Industry Co., Ltd.) was used.

[0086] 1.2 Experimental instruments and equipment: Hitachi UV-3010 ultraviolet-visible spectrophotometer (Hitachi, Japan), 1 / 100,000 balance (METTLER, Switzerland).

[0087] 2 Experimental methods

[0088] This experiment uses the DPPH free radical scavenging method to determine the antioxidant activity of each compound. Accurately weigh 2-hydroxy-5-methoxyfuran-3-carboxylic acid and BHA, and use methanol to prepare five series of sample solutions with concentrations of 12.5μM, 25μM, 50μM, 100μM and 200μM. In addition, the DPPH solution is prepared as needed, and an appropriate amount of DPPH is accurately weighed and used to prepare a solution with a concentration of 80μM with methanol. The whole process is protected from light. The specific operation is as follows: 1mL of sample solution is fully mixed with 1mL of DPPH solution, and placed at room temperature in a light-proof environment for 10 minutes. After setting the detection wavelength of the ultraviolet spectrophotometer to 517nm, the absorbance value of the sample is measured. Among them, methanol is used instead of the sample solution as the blank group, BHA is used instead of the sample solution as the positive control group, and a mixed solution of 1mL methanol and 1mL sample solution is used as the control group. The DPPH scavenging rate of each compound is calculated according to the following formula (A represents absorbance):

[0089] DPPH clearance rate (%) = (1-(A 样品 -A 对照 ) / A 空白 )×100%

[0090] 3 Experimental results

[0091] The experimental results show that the new compound of the present invention exhibits certain antioxidant activity, and the antioxidant effect is enhanced with the increase of the compound concentration, showing a dose-dependent trend.

[0092] The antioxidant activities of the novel compounds of the present invention are shown in Table 5.

[0093] Table 5: Antioxidant activity of compounds of the present invention.

[0094]

[0095] In summary, the present invention provides the compound 2-hydroxy-5-methoxyfuran-3-carboxylic acid and a method for its extraction and isolation. Separation, purification, and preparation are performed sequentially using water decoction, macroporous resin column chromatography, ODS column chromatography, Sephadex LH-20, and high-performance liquid chromatography. A new compound is successfully extracted and isolated. The method is simple, rapid, and environmentally friendly, and the compound isolated by this method is of high purity. Because the resulting compound is extracted from the commonly used traditional Chinese medicine Portulaca oleracea and exhibits anti-inflammatory, anticholinesterase, and antioxidant activities, the new compound 2-hydroxy-5-methoxyfuran-3-carboxylic acid and its salts and derivatives of the present invention may provide insights into drug development and have broad development prospects.

Claims

1. A furan carboxylic acid compound isolated from Portulaca oleracea, characterized in that: The molecular formula is: C6H6O5, and the chemical structure is: 。 2. The method for extracting and separating furan carboxylic acid compounds from Portulaca oleracea according to claim 1, characterized in that: The specific steps include: Step 1: Take dried purslane, decoct in water, concentrate the extract, and cool to room temperature to obtain a medicinal solution for later use; Step 2: The concentrated solution in step 1 is subjected to a macroporous resin, and eluted with water and ethanol of different concentrations. The 50% ethanol portion is recovered under reduced pressure to obtain an extract, and the concentrate is set aside; Step 3: The concentrate in step 2 was separated by ODS column, eluted with methanol-water gradient, detected by thin layer chromatography, and developed. The 5% methanol elution fraction was combined and evaporated to dryness to obtain a concentrate for use; Step 4: The concentrate obtained in step 3 is further separated by ODS column chromatography, using a methanol-water gradient elution, detected by thin layer chromatography, and color developed. The 20% methanol elution fractions are combined and evaporated to dryness to obtain a concentrate for use; Step 5: The product obtained in step 4 is further separated by pre-treated dextran gel column chromatography, and isocratically eluted with 30% methanol to obtain several elution fractions, which are detected by thin layer chromatography. The combined elution fractions are concentrated to dryness under reduced pressure and set aside; Step 6: The concentrate obtained in step 5 is separated and prepared by HPLC, and isocratic elution is performed using 0.1% by volume methanol-0.1% formic acid as the mobile phase to finally obtain the furan carboxylic acid compound.

3. The extraction and separation method according to claim 2, wherein In the step 1, the extraction is performed by decocting in water twice, each time for 2 hours, and the amount of water used is 8 to 16 times the amount of the medicinal material.

4. The extraction and separation method according to claim 2, wherein In step 2, the macroporous resin used is AB-8 macroporous resin, and the volume ratios of ethanol and water used are 30:70, 50:50, 70:30 and 100:

0.

5. The extraction and separation method according to claim 2, wherein: In step 3, the volume ratios of methanol and water used are 5:95, 20:80, 40:60, 80:20 and 100:0; and the particle size of ODS is 40-70 μm.

6. The extraction and separation method according to claim 2, characterized in that In step 4, the volume ratios of methanol and water used are 5:95, 20:80, 40:60, 80:20 and 100:0; and the particle size of ODS is 40-70 μm.

7. The extraction and separation method according to claim 2, characterized in that The pretreatment process of the ODS and dextran gel is as follows: soaking in methanol for 24 hours, loading onto the column, washing with methanol until no turbidity is observed when dripped into water, and then balancing with the initial mobile phase.

8. The extraction and separation method according to claim 2, characterized in that In step 6, the volume ratio of methanol to 0.1% formic acid is 20:80, and the retention time of the compound is 13.710 min.

9. Use of the furancarboxylic acid compound according to claim 1 in the preparation of anti-inflammatory drugs, anticholinesterase drugs and antioxidant drugs.

Images